Successful Treatment of Chromoblastomycosis caused by Cladophialophora carrionii with Itraconazole: Clinicopathology, Susceptibility, and Molecular Identification of a Case in Northern China

Yalong Li Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China;
Research Center for Medical Mycology, Peking University, Beijing, China;
National Clinical Research Center for Skin and Immune Diseases, Beijing, China

Search for other papers by Yalong Li in
Current site
Google Scholar
PubMed
Close
,
Yinggai Song Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China;
Research Center for Medical Mycology, Peking University, Beijing, China;
National Clinical Research Center for Skin and Immune Diseases, Beijing, China

Search for other papers by Yinggai Song in
Current site
Google Scholar
PubMed
Close
, and
Aiping Wang Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China;
Research Center for Medical Mycology, Peking University, Beijing, China;
National Clinical Research Center for Skin and Immune Diseases, Beijing, China

Search for other papers by Aiping Wang in
Current site
Google Scholar
PubMed
Close
Restricted access

Chromoblastomycosis (CBM), a prevalent subcutaneous mycosis in tropical and subtropical regions caused by dematiaceous fungi, often presents as refractory lesions. This case report details a 63-year-old woman from Tianjin, China, with CBM caused by Cladophialophora carrionii after plant trauma. Successful treatment with itraconazole was performed. After 3 months, the lesions improved significantly. The case highlights the importance of accurate diagnosis and tailored antifungal therapy, as well as the need for long-term follow-up because of the chronic nature of the disease.

Author Notes

Financial support: This study was supported by the National Key Research and Development Program of China (Grant no. 2023YFC2508200).

Disclosure: This study was approved by the Ethics Committee of Peking University First Hospital and was performed in compliance with the Declaration of Helsinki. The patient signed the informed consent form to participate in the study.

Current contact information: Yalong Li, Yinggai Song, and Aiping Wang, Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China, Research Center for Medical Mycology, Peking University, Beijing, China, and National Clinical Research Center for Skin and Immune Diseases, Beijing, China, E-mails: yalongli0430@163.com, syg3515@163.com, and wangap516@163.com.

Address correspondence to Yinggai Song or Aiping Wang, Dermatology and Venereology of Peking University First Hospital, 8 Xishiku St., Xicheng District, Beijing 100034, China. E-mails: syg3515@163.com or wangap516@163.com
Save